[IPO Watch] Strong Rebound After Post-Listing Decline! Jiangxi Bio (06915.HK) Surges Over 40% at One Point

On July 24, Jiangxi Bio<$JIANGXI BIO (06915.HK)$> shares continued to rally in the afternoon session, surging over 40% intraday to hit a new all-time high since listing. The stock closed at HK$12.81, up 24.49%, ranking among the top gainers on the Hong Kong Stock Exchange today.

Jiangxi Bio listed on June 30, 2026, at an issue price of HK$11.20. After breaking below its offering price on debut, the stock continued declining to HK$3.95, representing a sharp drop from the IPO price. This significant oversold condition created inherent technical demand for a rebound. Subsequently, within roughly two weeks, the company staged a remarkable turnaround, with its share price surging dramatically—posting a cumulative peak gain exceeding 200%—making it the standout recent biotech IPO in the Hong Kong market.

Beyond capital inflows, the company recently announced major positive developments, which may also be one of the underlying reasons driving heightened investor interest.

On the news front, Jiangxi Bio’s wholly owned subsidiary, Chifeng Boen Pharmaceutical, recently secured the Veterinary Drug Product Approval Number Certificate for its veterinary tetanus antitoxin (TAT) product. Veterinary TAT is primarily used for the prevention and treatment of tetanus infections in animals, providing passive immunity by neutralizing tetanus toxin in animals at risk of infection. The company’s board stated that this approval will further diversify its commercial product portfolio, moving beyond its reliance on human-use TAT alone and officially unlocking opportunities in the veterinary pharmaceuticals market.

The market’s strong reaction to the launch of its veterinary drug pipeline stems from its strategic significance, which far exceeds the incremental contribution of a single product. Jiangxi Bio had previously been heavily reliant on human-use TAT for revenue, leading investors to worry that this single-product dependency was capping its valuation. The veterinary TAT marks just the first step; the company’s self-developed pregnant mare serum gonadotropin (PMSG) is also nearing launch, with several other veterinary anti-infective drugs expected to make progress soon. Leveraging its existing antiserum platform technology and an overseas distribution network spanning more than 30 countries, the veterinary segment is poised for synergistic scale-up, establishing a second growth curve.

Overall, Jiangxi Bio’s recent rally reflects a confluence of an oversold bounce and fundamental catalysts. The gradual commercialization of its veterinary pipeline validates the company’s strategic shift from a single-product business toward a diversified biopharmaceutical platform, opening up meaningful medium- to long-term growth potential. However, as a newly listed stock with less than a month since IPO, it has a small free float and high volatility; after such a sharp short-term surge, investors should remain cautious of profit-taking risks.

Notably, the company’s sole cornerstone investor is Fource Holdings, controlled by Gong Hongjia—a prominent figure in healthcare investing—whose participation itself serves as a strong endorsement of the company’s long-term value.

The 13th edition of the Top 100 Hong Kong Stocks ranking is about to launch. As the undisputed leader in the antiserum niche, Jiangxi Bio’s scarcity value and industry position warrant attention. Historically, newly listed stocks have been a key source of new entrants to the Top 100 list, and whether the company can secure a spot through sustained earnings growth deserves ongoing monitoring.

36K Views